Vaginitis Therapeutics Market by Drug Type, Offering, Route of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image

Sale

Vaginitis Therapeutics Market by Drug Type, Offering, Route of Administration, Distribution Channel - Global Forecast 2025-2030

Report
186 Pages
October 2024
Region: Global
360iResearch™
ID: 5888952

UP TO €688EUR$697USD£574GBP OFF until Dec 31^st 2024

The Vaginitis Therapeutics Market grew from USD 2.60 billion in 2023 to USD 2.76 billion in 2024. It is expected to continue growing at a CAGR of 8.75%, reaching USD 4.68 billion by 2030.

The scope of vaginitis therapeutics encompasses treatments and interventions designed to manage and alleviate symptoms associated with vaginitis, including bacterial vaginosis, yeast infections, and trichomoniasis. The necessity for effective therapeutics in this domain stems from the high prevalence of vaginitis among women worldwide, underscoring the need for accessible, efficient, and patient-friendly solutions. Applications include both OTC and prescription medications, topical antifungals, antibiotics, probiotics, and emerging therapeutic vaccines. End-use scope spans diverse settings such as hospitals, clinics, and home care. Notably, the market's growth is influenced by rising awareness about women's health issues, increasing healthcare expenditures, and advancements in diagnostic technologies that enhance early detection capabilities. Key opportunities lie in the expansion of probiotic and biotic-based interventions, owing to their minimal side effects and non-invasive nature. Additionally, leveraging digital platforms for telemedicine can facilitate improved diagnosis and patient management. However, challenges such as regulatory hurdles, cultural stigmas, especially in developing regions, and antibiotic resistance present considerable limitations. The market also grapples with economic barriers that limit treatment access in lower-income demographics. Innovative areas for research include genomic research for precision medicine, development of broad-spectrum microbiota-modulating therapies, and AI-driven platforms for personalized treatment recommendations. Technological advancements in wearable health tech that monitor vaginal health could also drive future industry growth. The market is inherently dynamic, characterized by intense competition among players striving to develop novel therapeutic solutions. Companies must invest in robust R&D initiatives and strategic partnerships to stay competitive. An integrative approach combining traditional and alternative treatments could solidify a broader consumer base and address unmet clinical needs. By harnessing these insights, stakeholders can effectively navigate market complexities and capitalize on emerging growth avenues.

Understanding Market Dynamics in the Vaginitis Therapeutics Market

The Vaginitis Therapeutics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Rising prevalence of vaginitis caused by infections
- Increasing awareness about the impacts of sexual health on women
- Growing preference for minimally invasive medical procedures and advanced vaginal products
Market Restraints
- High cost associated with the treatment of vaginitis
Market Opportunities
- Technological advancement in diagnostics and therapeutics for treating vaginal infections
- Demand for targeted delivery systems such as gels and creams for treating vaginitis
Market Challenges
- Side effects associated with the use of vaginitis medications

Exploring Porter’s Five Forces for the Vaginitis Therapeutics Market

Porter’s Five Forces framework further strengthens the insights of the Vaginitis Therapeutics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Vaginitis Therapeutics Market

External macro-environmental factors deeply influence the performance of the Vaginitis Therapeutics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Vaginitis Therapeutics Market

The Vaginitis Therapeutics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Vaginitis Therapeutics Market

The Vaginitis Therapeutics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Vaginitis Therapeutics Market

The Vaginitis Therapeutics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaginitis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Cipla Ltd., Daré Bioscience, Inc., Dr Reddy's Laboratories Ltd, Eli Lilly and Company, Enzo Biochem Inc., Janssen Pharmaceuticals Inc., Lumavita AG, Lupin Pharmaceuticals Inc., Merck & Co., Inc., Mission Pharmacal Company, Mylan NV, Novartis AG, Novo Nordisk A/S, Perrigo Company plc, Pfizer Inc., PhagoMed Biopharma GmbH, Sanofi S.A., Starpharma Holdings Limited, Sun Pharmaceutical Industries Limited, TenNor Therapeutics Ltd, Teva Pharmaceutical Industries Ltd., and Tolmar Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Vaginitis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type
- Anti-bacterial
- Anti-fungal
- Hormone
Offering
- Over-The-Counter (OTC)
- Prescription
Route of Administration
- Oral
- Topical
Distribution Channel
- Hospital
- Pharmacies
  - Offline
  - Online

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of vaginitis caused by infections
5.1.1.2. Increasing awareness about the impacts of sexual health on women
5.1.1.3. Growing preference for minimally invasive medical procedures and advanced vaginal products
5.1.2. Restraints
5.1.2.1. High cost associated with the treatment of vaginitis
5.1.3. Opportunities
5.1.3.1. Technological advancement in diagnostics and therapeutics for treating vaginal infections
5.1.3.2. Demand for targeted delivery systems such as gels and creams for treating vaginitis
5.1.4. Challenges
5.1.4.1. Side effects associated with the use of vaginitis medications
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Vaginitis Therapeutics Market, by Drug Type

6.1. Introduction
6.2. Anti-bacterial
6.3. Anti-fungal
6.4. Hormone

7. Vaginitis Therapeutics Market, by Offering

7.1. Introduction
7.2. Over-The-Counter (OTC)
7.3. Prescription

8. Vaginitis Therapeutics Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Topical

9. Vaginitis Therapeutics Market, by Distribution Channel

9.1. Introduction
9.2. Hospital
9.3. Pharmacies
9.3.1. Offline
9.3.2. Online

10. Americas Vaginitis Therapeutics Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Vaginitis Therapeutics Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Vaginitis Therapeutics Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. VAGINITIS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. VAGINITIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
FIGURE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. VAGINITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. VAGINITIS THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTI-BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTI-FUNGAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HORMONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER (OTC), BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 39. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 40. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 41. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 44. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 46. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 62. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 66. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 68. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 71. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 73. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 76. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 77. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 81. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 82. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 83. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 86. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 91. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 92. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 96. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 101. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 102. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 106. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 107. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 111. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 113. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 116. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 117. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 127. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 129. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 132. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 134. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 137. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 138. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 139. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 142. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 143. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 144. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 147. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 148. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 149. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 152. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 153. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 157. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 158. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 159. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 172. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 173. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 174. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 177. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 179. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 182. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 183. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 184. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 202. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 203. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 204. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 212. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 213. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 214. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 217. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 218. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 219. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 232. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 233. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Vaginitis Therapeutics Market, which are profiled in this report, include:

AbbVie Inc.
Bausch Health Companies Inc.
Bayer AG
Cipla Ltd.
Daré Bioscience, Inc.
Dr Reddy's Laboratories Ltd
Eli Lilly and Company
Enzo Biochem Inc.
Janssen Pharmaceuticals Inc.
Lumavita AG
Lupin Pharmaceuticals Inc.
Merck & Co., Inc.
Mission Pharmacal Company
Mylan NV
Novartis AG
Novo Nordisk A/S
Perrigo Company plc
Pfizer Inc.
PhagoMed Biopharma GmbH
Sanofi S.A.
Starpharma Holdings Limited
Sun Pharmaceutical Industries Limited
TenNor Therapeutics Ltd
Teva Pharmaceutical Industries Ltd.
Tolmar Pharmaceuticals, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	186
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 2.76 Billion
Forecasted Market Value ( USD ) by 2030	$ 4.68 Billion
Compound Annual Growth Rate	8.7%
Regions Covered	Global
No. of Companies Mentioned	25

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3502EUR$3,545USD£2,918GBP €3891EUR$3,939USD£3,243GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6195EUR$6,272USD£5,163GBP €6883EUR$6,969USD£5,737GBP

Understanding Market Dynamics in the Vaginitis Therapeutics Market

Exploring Porter’s Five Forces for the Vaginitis Therapeutics Market

Applying PESTLE Analysis to the Vaginitis Therapeutics Market

Analyzing Market Share in the Vaginitis Therapeutics Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Vaginitis Therapeutics Market

Strategic Recommendations for Success in the Vaginitis Therapeutics Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Vaginitis Therapeutics Market Analysis & Forecast to 2024-2034

Vaginitis Therapeutics Global Market Report 2024

Vaginitis Therapeutics - Global Strategic Business Report

Vaginitis - Pipeline Insight, 2024

Vaginitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

About the Vaginitis Drug Market